Investor Relations
THE SHARE: Change: -0.25 SEK (-1.10%) / Price: 22.50 SEK / Oct 30, 2025, 2:14 pm (CET)
Press Releases
October 17, 2025 08:30 (CEST)
Genovis receives order worth approximately 1 million euros from global pharmaceutical company
Regulatory
MAR
July 24, 2025 08:30 (CEST)
Genovis Expands License Agreement to Access Proprietary Enzyme Technology for Therapeutic Antibody-Drug Conjugate Development
July 01, 2025 18:00 (CEST)
Genovis Exercises Call Option to Acquire Remaining Shares in SEQURNA, a fast-growing next-generation RNase inhibitors company
Regulatory
MAR
Financial Reports
February 14, 2025 08:00 (CET)
Strong momentum: 21% growth in enzyme business and significant improvement in earnings
Regulatory
MAR
Financial Calendar
- Q3 2025
November 7, 2025 - Q4 2025
February 12, 2026 - Q1 2026
April 28, 2026
